Anterior Cruciate Ligament Transection (ACLT)-Induced Osteoarthritis (OA) Model

Looking for a reliable partner to help you evaluate the efficacy of your drug candidates on osteoarthritis (OA)?  Look no further than Creative Bioarray. With our years of expertise in OA research, we have established a stable OA model induced by anterior cruciate ligament transection (ACLT) that ensures accurate and reliable results. Trust us to be your CRO partner for your OA drug development needs.

The ACLT model is the earliest well-known model and is currently the most widely used surgical model in OA research. The rationale for using this model is that ACL injury leads to joint destabilization, which in turn results in post-traumatic OA (PTOA). This model mimics the degradation of articular cartilage following ACL rupture. Compared to meniscectomy, the OA lesions in the ACLT model develop more slowly, making this model easier to use in pharmaceutical studies.

Our Anterior Cruciate Ligament Transection (ACLT)-Induced Osteoarthritis (OA) Model

  • Available Animal
    Rat
  • Modeling Method
    OA is surgically induced in the knee joint. After anesthetization, the surgical area is shaved and disinfected, and the right knee joint is subsequently exposed by dissecting the skin on the inside of the patella along the patellar tendon. The patella is dislocated laterally, the knee is placed in full flexion, and the anterior cruciate ligament is subsequently transected. After that, a positive anterior drawer test is performed to ensure complete transection of the ligament.
  • Endpoints
    • Body weight
    • Behavioral tests
    • Histology analysis (knee joint): H&E staining, Toluidine blue staining, Safranin O/Fast green staining
    • Cytokine analysis
    • Other customized endpoints

Example Data

Bilobalide attenuates ACLT-induced PTOA in rats via AMPK/SIRT1/mTOR pathway. (A) Mechanical sensitivity. (B) Vocalizations evoked by extension of the knee. (C) Representative images of the knee joint stained with hematoxylin-eosin (HE) and toluidine blue (TB) after 6 weeks of treatment.Fig. 1 Bilobalide attenuates ACLT-induced PTOA in rats via AMPK/SIRT1/mTOR pathway. (A) Mechanical sensitivity. (B) Vocalizations evoked by extension of the knee. (C) Representative images of the knee joint stained with hematoxylin-eosin (HE) and toluidine blue (TB) after 6 weeks of treatment.

Moreover, we also provide other OA models that maybe you are interested in:

Quotation and Ordering

Creative Bioarray has extensive experience and expertise in designing, validating, and analyzing animal efficacy studies. As a reliable partner, we are committed to providing high-quality services to our clients. If you are interested in our services, please feel free to contact us at any time or submit an inquiry to us directly. We look forward to cooperating with you.

References

  1. Ma, T., et al. Bilobalide exerts anti-inflammatory effects on chondrocytes through the AMPK/SIRT1/mTOR pathway to attenuate ACLT-induced post-traumatic osteoarthritis in rats. Frontiers in pharmacology, 2022, 13: 783506.
  2. Kubomura, D., et al. Evaluation of the chondroprotective action of N-acetylglucosamine in a rat experimental osteoarthritis model. Experimental and Therapeutic Medicine, 2017, 14(4): 3137-3144.
  3. Kuyinu, E.L., et al. Animal models of osteoarthritis: classification, update, and measurement of outcomes. Journal of orthopaedic surgery and research, 2016, 11: 1-27.

Explore Other Options

For research use only. Not for any other purpose.